Remove 2020 Remove Blogging Remove Invest Remove San Diego
article thumbnail

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Xconomy

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138
article thumbnail

Biopharma Execs Remain Optimistic Despite Political Headwinds

Xconomy

Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of 500 industry leaders and investors conducted by investment bank Jefferies.

Pricing 78
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Flagship Adds $1.1B for New Meds, More AI, & “Health Security”

Xconomy

Flagship Pioneering founder and CEO Noubar Afeyan didn’t know a global pandemic was in the cards for 2020 when he and his team laid out three new thematic areas of focus for the company last fall.

article thumbnail

California Accelerators Enroll Startups Targeting Cannabis Industry

Xconomy

On Monday, nine startups began a 16-week program at Canopy San Diego , a new accelerator program for seed-stage companies developing new technologies, products, and services to support the legal cannabis industry. By 2020, the cannabis industry is projected to hit $21.8 billion , according to ArcView Market Research.

article thumbnail

Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More

Xconomy

This week, the 2020 Nobel Prize in physiology or medicine was awarded to Harvey Alter, Michael Alton, and Charles Rice, whose research led to the discovery of the hepatitis C virus. Their work paved the way for blood tests and new medicines that can cure the infection.

article thumbnail

Can AI Tools, $76M Lead BlackThorn to Targeted Pysch Drugs?

Xconomy

The new Series B round will give San Francisco-based BlackThorn—a startup spun out of the Scripps Research Institute in 2013—the backing to run human tests of two experimental treatments. The other, for autism, could start a Phase 1 study in 2020. Those plans. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Tool 78